B7-H3 (CD276) is an immune checkpoint molecule aberrantly overexpressed on a wide range of tumour cells and associated stromal elements, while showing limited distribution in normal tissues. Its dual ...
Researchers from The University of Texas MD Anderson Cancer Center have developed a first-in-class antibody that targets a protein overexpressed in many cancer types, allowing for the creation of a ...
Researchers from Macrogenics Inc. presented preclinical efficacy data on MGC-026, an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody (MGA017) targeting B7-H3, linked to a ...
Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors. This is an ASCO Meeting ...
Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for ...
Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new ...
(RTTNews) - GT Biopharma, Inc. (GTBP) has submitted its investigational new drug (IND) application to the U.S. FDA for GTB-5550 TriKE, a novel natural killer (NK) cell engager designed to target B7-H3 ...
First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). First report of efficacy and safety results from a phase 2 ...
B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an antibody-drug conjugate targeting the immune checkpoint protein.
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results